B-type Natriuretic Peptide (BNP)
Evidence: CEvidence: BGrade C — Applies to native BNP physiology evidence. Nesiritide recombinant-product evidence is graded separately -- see Related Programme Evidence..
Grade B — Nesiritide (recombinant human BNP) clinical and regulatory programme.
Nesiritide is a manufactured recombinant human B-type natriuretic peptide with the same 32-amino-acid sequence as endogenous mature BNP. Its clinical programme includes randomized hemodynamic and acute-heart-failure trials and FDA-approved product labeling. The very large ASCEND-HF trial did not demonstrate significant improvement in death/heart-failure rehospitalization or the prespecified dyspnea endpoint and found more hypotension. These product-specific data must remain separate from the native BNP page's Grade C assessment of direct human peptide physiology.
Cardiovascular / Vascular
Evidence Snapshot
What this grade covers
Applies to native BNP physiology evidence. Nesiritide recombinant-product evidence is graded separately -- see Related Programme Evidence.
Regulatory Context
Native B-type Natriuretic Peptide is an endogenous hormone and is not itself an FDA-approved drug product. A recombinant form, Nesiritide (marketed as Natrecor), is FDA-approved as a separate regulated product -- see the related-programme evidence section; this does not mean every BNP preparation is FDA approved.
Research Takeaway
B-type Natriuretic Peptide (BNP) is a mature cardiac natriuretic peptide distinct from proBNP, NT-proBNP, ANP, CNP, and BNP metabolites.
Evidence boundary: Biomarker fragments such as NT-proBNP are not the same biologically active mature peptide.
See all 6 evidence claims →Quick Summary
B-type Natriuretic Peptide (BNP) is a mature cardiac hormone with direct human renal and cardiovascular physiology evidence. Nesiritide is a sequence-identical recombinant BNP drug product with a much larger clinical and regulatory evidence programme, including FDA labeling and the 7,141-patient ASCEND-HF trial; that product evidence is intentionally graded and described separately from native BNP.
Mechanism & Research Overview
B-type Natriuretic Peptide (BNP) is a mature cardiac hormone with direct human renal and cardiovascular physiology evidence. Nesiritide is a sequence-identical recombinant BNP drug product with a much larger clinical and regulatory evidence programme, including FDA labeling and the 7,141-patient ASCEND-HF trial; that product evidence is intentionally graded and described separately from native BNP.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
B-type Natriuretic Peptide (BNP) is a mature cardiac natriuretic peptide distinct from proBNP, NT-proBNP, ANP, CNP, and BNP metabolites.
Does not establish
Evidence boundary: Biomarker fragments such as NT-proBNP are not the same biologically active mature peptide.
Sources: Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man; Effects of B-type natriuretic peptide on cardiovascular biomarkers in healthy men
Supported
Exact human BNP-32 has been directly administered in controlled human studies and produces measurable renal, cardiovascular, and neurohormonal physiology.
Does not establish
Evidence boundary: Small experimental studies establish direct human pharmacology, not broad therapeutic efficacy.
Sources: Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man; Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects; Effects of B-type natriuretic peptide on cardiovascular biomarkers in healthy men; Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers
Supported
Nesiritide is a manufactured recombinant human BNP product with the same 32-amino-acid sequence as endogenous mature BNP.
Does not establish
Evidence boundary: Sequence identity does not erase regulatory, formulation, manufacturing, and clinical-programme distinctions between Nesiritide and arbitrary BNP preparations.
Supported
Nesiritide has randomized clinical-trial evidence in acute decompensated heart failure, but the 7,141-patient ASCEND-HF trial did not demonstrate a significant improvement in its major clinical efficacy outcomes.
Does not establish
Evidence boundary: This is a product-specific Nesiritide conclusion, not proof that native BNP lacks physiologic activity or that every BNP preparation has the same clinical profile.
Sources: Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial; Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure; Effect of nesiritide in patients with acute decompensated heart failure
Supported
Large randomized Nesiritide evidence identified hypotension as an important product-related safety signal while not showing an excess in 30-day death or worsening renal function in ASCEND-HF.
Does not establish
Evidence boundary: Safety findings apply to the studied Nesiritide product/regimen and do not establish long-term safety of unrelated BNP preparations.
Sources: Effect of nesiritide in patients with acute decompensated heart failure; NATRECOR (nesiritide) FDA prescribing information
Supported
NATRECOR (nesiritide), a recombinant human BNP product, has FDA-approved prescribing information; that approval is product-specific and must not be rewritten as approval of every BNP preparation.
Does not establish
Evidence boundary: Native endogenous BNP and regulated Nesiritide are scientifically related but not regulatorily interchangeable.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
BNP is biologically active in renal and cardiovascular regulation; administered peptide can alter renal handling and hemodynamics.Safety Consideration
Nesiritide carries product-specific hypotension risk in clinical trials/labeling.Safety Consideration
NT-proBNP/proBNP biomarker literature must not be treated as administration evidence for mature BNP.Safety Consideration
Nesiritide product approval and clinical evidence cannot be generalized to unregulated BNP preparations.
Research Areas Being Studied
Research areas discussed on this page reflect the Cardiovascular / Vascular category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers (2015):
- Effects of B-type natriuretic peptide on cardiovascular biomarkers in healthy men (2015):
- Effect of nesiritide in patients with acute decompensated heart failure (2011):
- Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure (2000):
- Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial (1999):
- Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects (1995):
- Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man (1994):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers | 2015 | Six healthy volunteers; double-blind three-way (or three-day) crossover comparing ANP, BNP, and CNP | Directly compared cerebral/systemic vascular responses to three natriuretic peptides (ANP, BNP, CNP) on separate study days/arms. | ||
| Effects of B-type natriuretic peptide on cardiovascular biomarkers in healthy men | 2015 | Ten healthy men; randomized placebo-controlled crossover | Four-hour BNP-32 infusion tested acute human biomarker/physiology effects. | ||
| Effect of nesiritide in patients with acute decompensated heart failure | 2011 | 7,141 hospitalized acute-heart-failure patients; randomized placebo-controlled | Nesiritide did not significantly change 30-day death/HF rehospitalization and did not meet the prespecified dyspnea efficacy threshold; hypotension was increased. | ||
| Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure | 2000 | Hospitalized decompensated heart failure patients | Nesiritide improved short-term hemodynamic measures and clinical status under trial protocol. | ||
| Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial | 1999 | Heart failure; randomized double-blind placebo-controlled | Nesiritide produced sustained acute hemodynamic effects in heart failure. | ||
| Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects | 1995 | Healthy subjects | BNP infusion altered indices of left ventricular relaxation/filling. | ||
| Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man | 1994 | Five healthy volunteers; randomized placebo-controlled crossover | Low-dose human BNP increased renal plasma flow, GFR, urine flow, and sodium excretion without major systemic hemodynamic change. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| NATRECOR (nesiritide) FDA prescribing information | 2019 | Official FDA labeling documents Nesiritide as recombinant human B-type natriuretic peptide and defines its regulated product use, warnings, and administration. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-25.
Follow research updates for B-type Natriuretic Peptide (BNP)
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.